![David Hastings](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Hastings
Finansdirektör/CFO på
TREVI THERAPEUTICS, INC.
Förmögenhet: 276 464 $ per 2026-05-31
Profil
David C.
Hastings is currently an Independent Director at SCYNEXIS, Inc. since 2015, an Independent Director at Entasis Therapeutics, Inc. since 2018, an Independent Director at Entasis Therapeutics Holdings, Inc. since 2018, and Chief Financial Officer at Trevi Therapeutics, Inc. starting in 2026.
Former roles include Finance Director at Sumitomo Pharma America, Inc. from 1994 to 1997, Independent Non-Executive Director at Vascular Biogenics Ltd. from 2018 to 2023, Chief Financial Officer & Executive Vice President at Incyte Corp.
from 2012 to 2014, Chief Financial Officer, Treasurer & VP at ArQule, Inc. from 2000 to 2003, Senior Manager at PricewaterhouseCoopers LLP in 1994, Vice President & Controller at Genzyme Corp.
from 1997 to 2000, Treasurer, Chief Financial & Accounting Officer at Unilife Corp.
from 2016 to 2017, and Chief Financial & Accounting Officer at Arbutus Biopharma Corp.
from 2019 to 2025.
Education includes undergraduate studies at the University of Vermont.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-03-30 | 58 391 ( 0,03 % ) | 266 263 $ | 2026-05-31 | |
SCYNEXIS, INC. 0,02 % | 2026-04-01 | 14 470 ( 0,02 % ) | 10 201 $ | 2026-05-31 |
Aktiva positioner av David Hastings
| Företag | Position | Start |
|---|---|---|
| SCYNEXIS, INC. | Direktör/Styrelseledamot | 2015-09-24 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Direktör/Styrelseledamot | 2018-04-01 |
| TREVI THERAPEUTICS, INC. | Finansdirektör/CFO | 2026-01-06 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for infectious diseases | Direktör/Styrelseledamot | 2018-04-01 |
Tidigare kända positioner av David Hastings
| Företag | Position | Slut |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Finansdirektör/CFO | 2025-03-28 |
| NOTABLE LABS, LTD. | Direktör/Styrelseledamot | 2023-10-16 |
| UNILIFE CORPORATION | Finansdirektör/CFO | 2017-06-05 |
| INCYTE CORPORATION | Finansdirektör/CFO | 2014-10-31 |
| ARQULE, INC. | Finansdirektör/CFO | 2003-09-01 |
David Hastingss utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
73
Första gradens relationer
13
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 13 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches and develops therapeutics to treat cancers & rare diseases | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, assurance, consulting and tax & business consulting services | Commercial Services |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Unilife Corp.
 Unilife Corp. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets syringes & other medical devices | Health Technology |
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
University of Vermont
 University of Vermont Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Develops novel treatments for atherosclerosis and cancer | Health Technology |
Trevi Therapeutics, Inc.
 Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for infectious diseases | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical biopharmaceutical company that engages in development of antibacterial products | Commercial Services |
